TY - JOUR T1 - Nivolumab-induced exocrine pancreatic insufficiency JF - Frontline Gastroenterology JO - Frontline Gastroenterol DO - 10.1136/flgastro-2021-102013 SP - flgastro-2021-102013 AU - Anna Jones AU - Kay Rodgers AU - Debbie Jeffrey AU - Waqas I Ali AU - HJN Andreyev Y1 - 2021/12/20 UR - http://fg.bmj.com/content/early/2021/12/19/flgastro-2021-102013.abstract N2 - Immune checkpoint inhibition is the standard-of-care for many advanced cancers. Side effects of therapy may prevent optimal treatment of the cancer. Management of side effects is dominated by recommendations derived from oncological, not gastroenterological practice. We report a patient who developed pancreatic insufficiency during checkpoint inhibitor therapy with a programmed cell death receptor 1 inhibitor, nivolumab, which if not diagnosed would have prevented ongoing treatment. This is a problem which affects approximately 1 in 100 patients treated with this agent but is rarely recognised. Gastroenterologists need to be aware of the spectrum of gastrointestinal disorders which occur after immunotherapy to treat cancer. ER -